BRITISH JOURNAL OF HAEMATOLOGY

Volume 118, Issue 1, July 2002

IMAGES IN HAEMATOLOGY

1 **Interesting splenic histology in a patient with advanced myelofibrosis**
I. Chandler and C. Delord

2 **Detection of implanted splenic tissue using 99m-Technetium-labelled heat-damaged autologous red cells**
J. de la Fuente, M. Deenamode and I. Dokal

REVIEWS

3 **Non-endocrine late complications of bone marrow transplantation in childhood: part I**
A. D. Leiper

23 **Non-endocrine late complications of bone marrow transplantation in childhood: part II**
A. D. Leiper

44 **Prevention and treatment of viral infections in stem cell transplant recipients**
P. Ljungman

58 **Endocrine late effects after bone marrow transplant**
B. M. D. Brennan and S. M. Shalet

TRANSPLANTATION

67 **Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)**
N. Kröger, T. Zabelina, P. Guardiola, V. Runde, J. Sierra, A. van Biezen, D. Niederwieser, A. R. Zander and T. de Witte

74 **Immune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery**
K. Kalwak, E. Gorczyńska, J. Toporski, D. Turkiewicz, M. Slociak, M. Ussowicz, E. Latos-Grażyńska, M. Król, J. Boguslawska-Jaworska and A. Chybicka

90 **Granulocyte colony-stimulating factor mobilized whole blood containing over $0{\cdot}3 \times 10^6$/kg $CD34^+$ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin's lymphoma**
A. R. Jonkhoff, A. M. de Kreuk, G. Franschman, J. van der Lelie, G. J. Schuurhuis, A. M. Dräger, S. Zweegman, P. C. Huijgens and G. J. Ossenkoppele

101 **Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults**
J. N. Barker, S. M. Davies, T. E. DeFor, L. J. Burns, P. B. McGlave, J. S. Miller and D. J. Weisdorf

108 **Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment**
M. B. C. Koh, H. G. Prentice, M. Corbo, M. Morgan, F. E. Cotter and M. W. Lowdell

117 **Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS® (v2·1) and Isolex® 300i (v2·5) clinical scale devices**
M. J. Watts, T. C. P. Somervaille, S. J. Ings, F. Ahmed, A. Khwaja, K. Yong and D. C. Linch

Short reports

124 **Stem cell transplantation for paroxysmal nocturnal haemoglobinuria in childhood**
C. Flotho, B. Strahm, U. Kontny, U. Duffner, A. M. J. Peters, W. Dupuis and C. M. Niemeyer

128 **Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor**
Y. Kanda, R. Tanosaki, K. Nakai, T. Saito, M. Ohnishi, H. Niiya, A. Chizuka, K. Yakushijin, N. Urahama, K. Ueda, K. Iijima, T. Ando, H. Matsubara, M. Kami, A. Makimoto, Y. Kobayashi, K. Tobinai, S. Mineishi and Y. Takaue

132 **Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning**
M. Mitterbauer, P. Kalhs, F. Keil, E. Prinz, K. Moser, C. Mannhalter, G. Mitterbauer, S. Brugger, H. Gisslinger, K. Lechner and H. T. Greinix

136 **Analysis of T-cell repertoire and mixed chimaerism in a patient with aplastic anaemia after allogeneic bone marrow transplantation**
Y. Tsutsumi, J. Tanaka, J. Sugita, N. Kato, L. Zhang, M. Yonezumi, K. Chiba, N. Toyosima, T. Kondo, S. Ohta, A. Mori, S. Hasino, M. Asaka and M. Imamura

140 **A clinical comparison of unrelated cord blood transplantation and unrelated bone marrow transplantation for adult patients with acute leukaemia in complete remission**
J. Ooi, T. Iseki, S. Takahashi, A. Tomonari, H. Nagayama, K. Ishii, K. Ito, H. Sato, T. Takahashi, M. Shindo, R. Sekine, N. Ohno, K. Uchimaru, F. Nagamura, N. Shirafuji, A. Tojo, K. Tani and S. Asano

144 **Infusion of peripheral blood stem cells collected at diagnosis, with maintenance of the treatment, resulted in Ph-negative recovery in a chronic myeloid leukaemia patient in persisting aplasia on STI-571 therapy**
P. Lewalle, N. Meuleman, A. Verhest, D. Bron and P. Martiat

HAEMATOLOGICAL MALIGNANCY

147 **Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia**
A. Sauerbrey, W. Sell, D. Steinbach, A. Voigt and F. Zintl

151 **Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome**
S. Verstovsek, E. Estey, T. Manshouri, F. J. Giles, J. Cortes, M. Beran, A. Rogers, M. Keating, H. Kantarjian and M. Albitar

157 **Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells**
M. A. Frassanito, A. Cusmai, C. Piccoli and F. Dammacco

166 **Monoclonal gammopathy in Iceland: a population-based registry and follow-up**
H. M. Ögmundsdóttir, V. Haraldsdóttir, G. M. Jóhannesson, G. Ólafsdóttir, K. Bjarnadóttir, H. Sigvaldason and H. Tulinius

174 **Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients**
E. Terpos, A. Mougiou, A. Kouraklis, A. Chatzivassili, E. Michalis, N. Giannakoulas, E. Manioudaki, A. Lazaridou, V. Bakaloudi, M. Protopappa, D. Liapi, E. Grouzi, A. Parharidou, A. Symeonidis, G. Kokkini, N. P. Laoutaris, G. Vaipoulos, N. I. Anagnostopoulos, J. I. Christakis, J. Meletis, K. L. Bourantas, N. C. Zoumbos, X. Yataganas and N.-A. Viniou for The Greek MDS Study Group

181 **Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor**
S. Kasahara, T. Hara, H. Itoh, K. Ando, H. Tsurumi, M. Sawada, T. Yamada, H. Ohnishi and H. Moriwaki

189 **Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation**
V. Delwail, J.-P. Jais, P. Colonna and J.-M. Andrieu for the GOELAMS (Groupe Ouest Est d'Étude des Leucémies and Autres Maladies du Sang)

195 **Interleukin 6 expression by Hodgkin/Reed–Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease**
G. M. Reynolds, L. J. Billingham, L. J. Gray, J. R. Flavell, S. Najafipour, J. Crocker, P. Nelson, L. S. Young and P. G. Murray

202 **Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production**
A. Kosmaczewska, I. Frydecka, D. Boćko, L. Ciszak and R. Teodorowska

210 **Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study**
C. Dumontet, N. Mounier, J. N. Munck, A. Bosly, F. Morschauser, D. Simon, G. Marit, O. Casasnovas, O. Reman, T. Molina, F. Reyes and B. Coiffier

218 **The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies**
S. Cortelazzo, A. Rossi, E. Oldani, T. Motta, R. Giardini, P. L. Zinzani, E. Zucca, H. Gomez, A. J. M. Ferreri, G. Pinotti, C. Chini, L. Devizzi, A. M. Gianni, F. Cavalli and T. Barbui on behalf of the International Extranodal Lymphoma Study Group (IELSG)

229 **Low-dose doxorubicin-induced necrosis in Jurkat cells and its acceleration and conversion to apoptosis by antioxidants**
K. Sugimoto, K. Tamayose, M. Sasaki, K. Hayashi and K. Oshimi

Short reports

239 **Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect**
A. Martín, R. García-Sanz, J. Hernández, J. Bladé, B. Suquía, J. Fernández-Calvo, M. González, G. Mateo, A. Orfao and J. F. San Miguel

243 **Appearance of del(11q) in two patients with acute promyelocytic leukaemia treated with all-*trans* retinoic acid and combination chemotherapy**
L. J. Campbell, K. C. Rayeroux, K. Arkell, J. V. Catalano and M. F. Cole-Sinclair

246 **Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes**
R. Invernizzi, A. Pecci, E. Travaglino, P. G. Gobbi, L. Malabarba, I. Ramajoli and E. Ascari

251 **Blast crisis of Philadelphia chromosome-positive chronic myeloid leukaemia carrying micro-bcr breakpoint (e19a2 and e191a)**
A. Ohsaka, S. Hoshino, M. Kobayashi, H. Kudo and R. Kawaguchi

PLATELETS, HAEMOSTASIS AND THROMBOSIS

255 **Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors**
A. Vayá, Y. Mira, F. Ferrando, Mª T. Contreras, A. Estelles, F. España, D. Corella and J. Aznar

260 **A Leu7Pro mutation in the signal peptide of platelet glycoprotein (GP)IX in a case of Bernard–Soulier syndrome abolishes surface expression of the GPIb–V–IX complex**
F. Lanza, C. de la Salle, M.-J. Baas, A. Schwartz, B. Boval, J.-P. Cazenave and J. P. Caen

267 **Factor V Leiden in central venous catheter-associated thrombosis**
R. Fijnheer, B. Paijmans, L. F. Verdonck, H. K. Nieuwenhuis, M. Roest and A. W. Dekker

Short reports

271 **Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura**
F. Langer, F. Bergmann, U. Budde, S. Hegewisch-Becker and D. K. Hossfeld

275 **Diagnostic value of D-dimer in patients with a moderate pretest probability of deep venous thrombosis**
C. Aguilar, A. Martinez, A. Martinez, C. Del Rio, M. Vazquez and F J. Rodriguez

278 **Mutations in coagulation factor XIII A gene in three Turkish patients: two novel mutations and a known insertion**
E. Birben, R. Öner, C. Öner, F. Gümrük, C. Altay and A. Gürgey

HAEMOPOIESIS AND LEUCOCYTES

282 **Reciprocal alterations of Th1/Th2 function in γδ T-cell subsets of human immunodeficiency virus-1-infected patients**
T. S. Dobmeyer, R. Dobmeyer, D. Wesch, E. B. Helm, D. Hoelzer and D. Kabelitz

289 **All-*trans* retinoic acid prevents apoptosis of human marrow CD34$^+$ cells deprived of haematopoietic growth factors**
O. Herault, J. Domenech, M. T. Georget, N. Clement, P. Colombat and C. Binet

296 **Characterization of granulocyte colony-stimulating factor receptor expressed on human lymphocytes**
K. Morikawa, S. Morikawa, M. Nakamura and T. Miyawaki

305 **The co-expression of CD117 (c-kit) and osteocalcin in activated bone marrow stem cells in different diseases**
R. Huss and S. Moosmann

313 **Treatment responses of childhood aplastic anaemia with chromosomal aberrations at diagnosis**
S. Ohga, A. Ohara, S. Hibi, S. Kojima, F. Bessho, S. Tsuchiya, Y. Ohshima, N. Yoshida, Y. Kashii, S. Nishimura, K. Kawakami, K. Nishikawa and I. Tsukimoto for the Aplastic Anaemia Committee of the Japanese Society of Paediatric Haematology

320 **Reduced function of the multidrug resistance P-glycoprotein in CD34$^+$ cells of patients with aplastic anaemia**
R. T. Calado, A. B. Garcia, D. A. P. Gallo and R. P. Falcão

Short report

327 **Severe aplastic anaemia and Grave's disease in a paediatric patient**
M. Kumar and J. Goldman

RED CELLS

330 **The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients**
A. Ceci, P. Baiardi, M. Felisi, M. D. Cappellini, V. Carnelli, V. De Sanctis, R. Galanello, A. Maggio, G. Masera, A. Piga, F. Schettini, I. Stefano and F. Tricta

337 ***In vitro* effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent**
E. W. Iyamu, E. A. Turner and T. Asakura

CORRESPONDENCE

344 **Bilateral simultaneous central retinal vein occlusion (CRVO) caused by Waldenstrom's macroglobulinaemia with acquired von Willebrand's disease**
P. Z. Casares, D. S. Gillet, D. H. Verity and N. R. Rowson

345 **Mitochondrial oxygen consumption and ineffective haematopoiesis in patients with myelodysplastic syndromes**
D. Bowen and C. Peddie

346 **Reply to Bowen and Pettie**
T. Matthes

347 **Analysis of durability of response to thalidomide treatment for relapsed myeloma patients**
B. Myers and G. Dolan

348 **ANNOUNCEMENT**

Volume 118, Issue 2, August 2002

IMAGES IN HAEMATOLOGY

349 **Sequential fluorescence *in situ* hybridization for the quantification of minimal residual disease in recipient cells after sex-mismatched allogeneic stem cell transplantation**
I. Buño, E. Moreno-Lopez and J. L. Diez-Martin

350 **The natural history of a solitary plasmacytoma**
A. Corso

CURRENT CONTROVERSIES: WHICH PATIENTS WITH ACUTE MYELOID LEUKAEMIA SHOULD RECEIVE A BONE MARROW TRANSPLANTATION?

351 **1) A statistician's view**
K. Wheatley

357 **2) An adult treater's view**
A. K. Burnett

365 **3) A European view**
U. Creutzig and D. Reinhardt

378 **4) An American view**
A. R. Chen, T. A. Alonzo, W. G. Woods and R. J. Arceci

ACUTE MYELOID LEUKAEMIA

385 **The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial**
A. K. Burnett, K. Wheatley, A. H. Goldstone, R. F. Stevens, I. M. Hann, J. H. K. Rees and G. Harrison on behalf of the Medical Research Council Adult and Paediatric Working Parties

401 **Superior effect of 9-*cis* retinoic acid (RA) compared with all-*trans* RA and 13-*cis* RA on the inhibition of clonogenic cell growth and the induction of apoptosis in OCI/AML-2 subclones: is the p53 pathway involved?**
P. Koistinen, A. Zheng, M. Säily, T. Siitonen, P. Mäntymaa and E.-R. Savolainen

411 **Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion**
B. A. van der Reijden, A. Simons, E. Luiten, S. C. van der Poel, P. E. Hogenbirk, E.Tönnissen, P. J. M. Valk, B. Löwenberg, G. E. De Greef, M. H. Breuning and J.H.Jansen

419 **Simultaneous induction of matrix metalloproteinase-9 and interleukin 8 by all-*trans* retinoic acid in human PL-21 and NB4 myeloid leukaemia cells**
M. Shibakura, K. Niiya, T. Kiguchi, K. Shinagawa, F. Ishimaru, K. Ikeda, M. Namba, Y.Nakata, M. Harada and M. Tanimoto

426 **Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients**
T. Haferlach, C. Schoch, S. Schnittger, W. Kern, H. Löffler and W. Hiddemann

Short reports

432 **SAB – a promising new treatment to improve remission rates in AML in the elderly?**
K. Wheatley

434 **Assessment of caspase activity as a possible prognostic factor in acute myeloid leukaemia**
L. Oliver, F. Vavasseur, B. Mahé, P. Perrin, J.-L. Harousseau, K. Meflah and F.-M. Vallette

438 **Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?**
M. Breccia, M. C. Petti, E. Ottaviani, M. Mancini, G. M. D'Elia, S. Mecarocci and G. Alimena

442 **Persistent aplasia after chemotherapy for acute myeloid leukaemia treated with stem cell transplantation from a matched unrelated donor after dose-reduced conditioning**
L. Hambach, G. Heil, B. Hertenstein and A. Ganser

HAEMATOLOGICAL MALIGNANCY

445 **Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI**
J. M. Chessells, G. Harrison, S. M. Richards, B. E. Gibson, C. C. Bailey, F. G. H. Hill and I. M. Hann for the Medical Research Council Working Party on Childhood Leukaemia

456 **Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry**
C. R. Pinkerton, I. Hann, C. L. Weston, T. Mapp, A. Wotherspoon, R. Hobson, D. A. Kelly, D. Vergani, D. Hadzic, L. Rees, M. Burke and J. A. Thomas

462 **DNA microarray analysis of T cell-type lymphoproliferative disease of granular lymphocytes**
H. Makishima, F. Ishida, T. Ito, K. Kitano, S. Ueno, K. Ohmine, Y. Yamashita, J. Ota, M. Ota, K. Yamauchi and H. Mano

470 **Reliability of lymphoma classification in bone marrow trephines**
T. Buhr, F. Länger, J. Schlué, R. von Wasielewski, U. Lehmann, D. Braumann and H. Kreipe

477 **Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk**
I. Kerridge, L. Lincz, F. Scorgie, D. Hickey, N. Granter and A. Spencer

482 **Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma**
T. Yoshino, S. Nakamura, J. Suzumiya, N. Niitsu, K. Ohshima, J. Tsuchiyama, K. Shinagawa, M. Tanimoto, Y. Sadahira, M. Harada, M. Kikuchi and T. Akagi

488 **CD95 (Fas) expression is regulated by sequestration in the Golgi complex in B-cell lymphoma**
A. P. Haynes, I. Daniels, A. M. Abhulayha, G. I. Carter, R. Metheringham, C. D. Gregory and B. J. Thomson

495 **β_2-microglobulin as a negative growth regulator of myeloma cells**
R. Min, Z. Li, J. Epstein, B. Barlogie and Q. Yi

506 **Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells**
A. Bashey, M. J. Cantwell and T. J. Kipps

514 **A molecular study of the t(4;14) in multiple myeloma**
K. Sibley, J. A. L. Fenton, A. M. Dring, A. J. Ashcroft, A. C. Rawstron and G. J. Morgan

521 **The anti-apoptotic genes Bcl-X_L and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic $CD34^+$ cells**
M. Konopleva, S. Zhao, W. Hu, S. Jiang, V. Snell, D. Weidner, C. E. Jackson, X. Zhang, R. Champlin, E. Estey, J. C. Reed and M. Andreeff

535 **Phosphatidylinositol 3-kinases are involved in the all-*trans* retinoic acid-induced upregulation of CD38 antigen on human haematopoietic cells**
D. Lewandowski, C. Linassier, S. Iochmann, M. Degenne, J. Domenech, P. Colombat, C. Binet and O. Hérault

545 **Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase *in situ* hybridization monitoring in monoclonal gammopathies of undetermined significance**
P. Bernasconi, P. M. Cavigliano, M. Boni, C. Astori, S. Calatroni, I. Giardini, B. Rocca, M. Caresana, N. Crosetto, M. Lazzarino and C. Bernasconi

550 **JH probe real-time quantitative polymerase chain reaction assay for Bcl-2/IgH rearrangements**
M. J. Jenner, K. E. Summers, A. J. Norton, J. A. Amess, R. S. Arch, B. D. Young, T. A. Lister, J. Fitzgibbon and L. K. Goff

Short reports

559 **Philadelphia chromosome-positive mature B-cell (Burkitt cell) leukaemia**
G. Mann, M. M. Trebo, O. A. Haas, E. R. Grümayer-Panzer, M. N. Dworzak, T. Lion and H. Gadner

563 **The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction**
K. E. Summers, A. J. Davies, J. Matthews, M. J. Jenner, V. Cornelius, J. A. Amess, A. J. Norton, A. Z. S. Rohatiner, J. Fitzgibbon, T. A. Lister and L. K. Goff

567 **Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature**
R. D. Baird, R. N. van Zyl-Smit, T. Dilke, S. E. Scott and S. M. B. Rassam

PLATELETS, HAEMOSTASIS AND THROMBOSIS

569 **Possible role of Marcks in the cellular modulation of monocytic tissue factor-initiated hypercoagulation**
A. J. Chu, S.-H. Lin and E. Piasentin

577 **Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus**
J. Nojima, H. Kuratsune, E. Suehisa, T. Kawasaki, T. Machii, T. Kitani, Y. Iwatani and Y. Kanakura

584 **Effect of *Helicobacter pylori* eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura**
K. Kohda, T. Kuga, K. Kogawa, Y. Kanisawa, K. Koike, G. Kuroiwa, Y. Hirayama, Y. Sato, T. Matsunaga and Y. Niitsu

589 **A Tyr346 → Cys substitution in the interdomain acidic region *a1* of factor VIII in an individual with factor VIII:C assay discrepancy**
A. D. Mumford, M. Laffan, J. O'Donnell, J. H. McVey, D. J. D. Johnson, R. A. Manning and G. Kemball-Cook

595 **Mutations in the thrombomodulin gene are rare in patients with severe thrombophilia**
E. M. Faioni, F. Franchi, G. Castaman, E. Biguzzi and F. Rodeghiero

600 **The role of strain gauge plethysmography in the assessment of patients with suspected deep vein thrombosis**
B. J. Robinson, P. J. L. Kesteven and S. T. Elliott

604 **Protein C inhibitor (plasminogen activator inhibitor-3) and the risk of venous thrombosis**
J. C. M. Meijers, J. A. Marquart, R. M. Bertina, B. N. Bouma and F. R. Rosendaal

610 **Prothrombin A19911G and G20210A polymorphisms' role in thrombosis**
E. Pérez-Ceballos, J. Corral, I. Alberca, A. Vayá, P. Llamas, R. Montes, R. González-Conejero and V. Vicente

Short report 615 **Protein C/S ratio, an accurate and simple tool to identify carriers of a protein C gene mutation**
E. J. Libourel, J. R. Meinardi, P.-J. de Kam, R. Veenstra, W. van der Schaaf, M. H. J. Ruiters and J. van der Meer

HAEMOPOIESIS AND LEUCOCYTES

619 **Erythroid 5-aminolevulinate synthase, ferrochelatase and DMT1 expression in erythroid progenitors: differential pathways for erythropoietin and iron-dependent regulation**
H. Zoller, C. Decristoforo and G. Weiss

627 **Transforming growth factor-β1 causes transcriptional activation of CD34 and preserves haematopoietic stem/progenitor cell activity**
L. Pierelli, M. Marone, G. Bonanno, S. Rutella, D. de Ritis, S. Mancuso, G. Leone and G. Scambia

638 **MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-α expression in human myelomonocytic cells**
J. Wang, M. Kobayashi, M. Han, S. Choi, M. Takano, S. Hashino, J. Tanaka, T. Kondoh, K.-i. Kawamura and M. Hosokawa

646 **Protein kinase C-ζ overexpression induces erythroid phenotype in the monocytic leukaemia cell line U937**
V. Mansat-De Mas, A. de Thonel, V. Gaulin, C. Demur, G. Laurent and A. Quillet-Mary

654 **Induction and characterization of cutaneous lymphocyte antigen on natural killer cells**
J. Tsuchiyama, T. Yoshino, K. Toba, N. Harada, R. Nishiuchi, T. Akagi, T. Furukawa, M. Takahashi, I. Fuse, Y. Aizawa and M. Harada

RED CELLS

663 **The membrane characteristics of *Plasmodium falciparum*-infected and -uninfected heterozygous α^0thalassaemic erythrocytes**
T. N. Williams, D. J. Weatherall and C. I. Newbold

671 **The β-globin C → G mutation at 6 bp 3′ to the termination codon causes β-thalassaemia by decreasing the mRNA level**
A. Sgourou, A. Papachatzopoulou, L. Psiouri, M. Antoniou, N. Zoumbos, R. Gibbs and A. Athanassiadou

TRANSFUSION

677 **The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy**
C. R. Callow, R. Swindell, W. Randall and R. Chopra

CORRESPONDENCE

683 **Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia**
A. Manoharan

684 **Myeloid/natural killer cell precursor acute leukaemia with minor BCR/ABL mRNA transcript**
J. Ikewaki, E. Otsuka, J. Satou, F. Miya, T. Nakayama, H. Kikuchi, K. Kashima and M. Nasu

686 **ANNOUNCEMENT**

Volume 118, Issue 3, September-I 2002

IMAGES IN HAEMATOLOGY

687 **Giant cell arteritis detected by bone marrow trephine**
P. A. Cahalin and J. Pawade

688 **Bladder chloroma complicating refractory anaemia with excess of blasts**
P. Kerr, R. Evely and J. Pawade

REVIEWS

689 **Factor VII deficiency**
D. J. Perry

701 **Shwachman–Diamond syndrome**
Y. Dror and M. H. Freedman

714 **Chromatin modification, leukaemia and implications for therapy**
L. K. Jones and V. Saha

728 **Immunotherapy for post-transplant lymphoproliferative disease**
K. C. M. Straathof, B. Savoldo, H. E. Heslop and C. M. Rooney

HAEMATOLOGICAL MALIGNANCY

741 **A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group**
A. M. Testi, I. Del Giudice, W. Arcese, M. L. Moleti, F. Giona, G. Basso, A. Biondi, V. Conter, C. Messina, R. Rondelli, A. Micozzi, C. Micalizzi, E. Barisone, F. Locatelli, G. Dini, M. Aricò, F. Casale, M. Comis, S. Ladogana, A. Lippi, R. Mura, M. F. Pinta, N. Santoro, M. G. Valsecchi, G. Masera and F. Mandelli from the AIEOP Cooperative Group

748 **High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia**
H. Hallböök, B. Simonsson, T. Ahlgren, M. Björkholm, J. Carneskog, G. Grimfors, R. Hast, K. Karlsson, E. Kimby, R. Lerner, O. Linder, M. Linderholm, E. Löfvenberg, C. Malm, P.-G. Nilsson, C. Paul, L. Stenke, D. Stockelberg, U. Tidefelt, I. Turesson, A.-M. Uden-Blome, L. Vilen, A. Wahlin, I. Winquist and B. Smedmyr

755 **Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia**
T. Mainou-Fowler, H. Dignum, P. R. A. Taylor, A. M. Dickinson, P. W. G. Saunders, S. J. Proctor and G. P. Summerfield

762 **The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase**
E. Olavarria, J. Reiffers, C. Boque, A. Sureda, G. Meloni, M. Michallet, R. E. Clark, D. Blaise, A. M. Carella, J.-Y. Cahn, J. P. Jouet, V. Rizzoli, A. Van Biezen, A. Gratwohl, J. M. Goldman, D. Niederwieser and J. F. Apperley for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

771 **Serial monitoring of BCR–ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia**
L. Wang, K. Pearson, L. Pillitteri, J. E. Ferguson and R. E. Clark

778 **Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma**
C. Zheng, M. Ostad, M. Andersson, F. Celsing, G. Holm and A. Sundblad

786 **Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients**
F. Cervantes, A. Alvarez-Larrán, C. Talarn, M. Gómez and E. Montserrat

791 **Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma**
C. Villalva, P. Trempat, C. Greenland, C. Thomas, J. P. Girard, F. Moebius, G. Delsol and P. Brousset

799 **Safety of allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma**
Q. Sun, R. Burton, V. Reddy and K. G. Lucas

Short reports

809 **Differentiation between non-Hodgkin's lymphoma recurrence and second primary lymphoma by VDJ rearrangement analysis**
M. Libra, V. De Re, D. Gasparotto, A. Gloghini, A. Marzotto, I. Milan, U. Tirelli, F. Stivala, A. Carbone and M. Boiocchi

813 **Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia**
D. P. Steensma, C. C. Hook, S. L. Stafford and A. Tefferi

817 **Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients**
G. Pruneri, M. Ponzoni, A. J. M. Ferreri, N. Decarli, M. Tresoldi, F. Raggi, C. Baldessari, M. Freschi, L. Baldini, M. Goldaniga, A. Neri, N. Carboni, F. Bertolini and G. Viale

821 **Strontium-89: a novel treatment for a case of osteosclerotic myeloma associated with life-threatening neuropathy**
A. J. Sternberg, P. Davies, C. Macmillan, A. Abdul-Cader and S. Swart

PLATELETS, HAEMOSTASIS AND THROMBOSIS

825 **Factor XIII A-subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy, middle-aged men**
H. P. Kohler, R. A. S. Ariëns, A. J. Catto, A. M. Carter, G. J. Miller, J. A. Cooper, M. W. Mansfield, K. F. Standeven and P. J. Grant

Short reports

833 **A Leu^{55} to Pro substitution in the integrin α_{IIb} is responsible for a case of Glanzmann's thrombasthenia**
S. Tanaka, T. Hayashi, Y. Hori, C. Terada, K. S. Han, H. S. Ahn, F. Bourre and Y. Tani

836 **High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura**
A. S. Levy, S. Cunningham-Rundles, B. Mazza, M. Simm, R. Gorlick and J. Bussel

839 **Use of a non-depleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX**
N. Salooja, G. Kemball-Cook, E. G. D. Tuddenham and J. Dyson

843 **The effect of plasma caeruloplasmin levels on the sensitivity for activated protein C**
M. C. H. de Visser, J. H. M. Souverijn, F. R. Rosendaal and R. M. Bertina

HAEMOPOIESIS AND LEUCOCYTES

847 **Influence of lineage-specific cytokines on commitment and asymmetric cell division of haematopoietic progenitor cells**
L. Chen, J. Zhang, D. C. Tang, E. Fibach and G. P. Rodgers

858 **The role of common gamma chain in human monocytes *in vivo*; evaluation from the studies of X-linked severe combined immunodeficiency (X-SCID) carriers and X-SCID patients who underwent cord blood stem cell transplantation**
T. Ariga, K. Yamaguchi, J. Yoshida, A. Miyanoshita, T. Watanabe, T. Date, J.-i. Miura, S. Kumaki, N. Ishii and Y. Sakiyama

864 **Improvement of interleukin 2 production, clonogenic capability and restoration of stromal cell function in human immunodeficiency virus-type-1 patients after highly active antiretroviral therapy**
A. Isgrò, A. Aiuti, I. Mezzaroma, M. Addesso, E. Riva, A. Giovannetti, F. Mazzetta, C. Alario, A. Mazzone, L. Ruco and F. Aiuti

875 **Retroviral interleukin 1α gene transfer in bone marrow stromal cells in a primate model: induction of myelopoiesis stimulation**
T. de Revel, N. Becard, T. Sorg, S. Rousseau, J. P. Spano, H. Thiebot, M. Methali, G. Gras, R. Le Grand and D. Dormont

885 **Human natural killer cell development in a xenogeneic culture system**
I. Barão, F. Vaz, G. Almeida-Porada, E. F. Srour, E. D. Zanjani and J. L. Ascensão

RED CELLS

893 **Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/β-thalassaemic patients**
V. Atichartakarn, P. Angchaisuksiri, K. Aryurachai, S. Onpun, S. Chuncharunee, A. Thakkinstian and K. Atamasirikul

899 **Glycophorin A-mediated haemolysis of normal human erythrocytes: evidence for antigen aggregation in the pathogenesis of immune haemolysis**
M. C. Brain, J. M. Prevost, C. E. Pihl and C. B. Brown

909 **Enforced expression of HOX11 is associated with an immature phenotype in J2E erythroid cells**
W. K. Greene, J. Ford, D. Dixon, P. A. Tilbrook, P. M. Watt, S. P. Klinken and U. R. Kees

Short report 918 **Etilefrine for the prevention of priapism in adult sickle cell disease**
I. Okpala, N. Westerdale, T. Jegede and B. Cheung

CORRESPONDENCE

922 **Time for a redefinition of type 2M von Willebrand disease**
D. Keeling

922 **Polyclonal hypergammaglobulinaemia with hyperviscosity syndrome**
B. Paul

923 **Possibility of somatic mosaicism of *ELA2* mutation overlooked in an asymptomatic father transmitting severe congenital neutropenia to two offspring**
K. F. Benson and M. Horwitz

923 **Reply to Benson and Horwitz**
M. Germeshausen, M. Ballmaier and K. Welte

924 **The use of vitamin K for reversal of over-warfarinization in children**
P. Bolton-Maggs and L. Brook

925 **Reversal of coumarin-induced over-anticoagulation**
M. A. Escobar

926 **Reply to Escobar**
M. Makris and H. G. Watson

927 **Regarding the loss of CD20 after rituximab therapy**
R. Lee and R. C. Braylan
927 **Consequences at mRNA level of the PKLR gene splicing mutations IVS10(+1)G→C and IVS8(+2)T→G causing pyruvate kinase deficiency**
L. Manco, C. Bento, M. L. Ribeiro and G. Tamagnini
929 **BOOK REVIEWS**
930 **ANNOUNCEMENTS**

Volume 118, Issue 4, September-II 2002

IMAGES IN HAEMATOLOGY

931 **Severe autoimmune neutropenia associated with bone marrow sea-blue histiocytosis**
H. A. Papadaki, H. Michelakaki, J. Bux and G. D. Eliopoulos
932 **Graft-versus-host disease: the face of the aggressor**
C. J. M. van Noesel, M. de Wit and C. E. M. Hollak

REVIEW

933 **Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults**
D. Provan and A. Newland

ANNOTATION

945 **Translation of cure for acute lymphoblastic leukaemia to all children**
T. O. B. Eden

HAEMATOLOGICAL MALIGNANCY

952 **Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia**
R. Ruchlemer, A. C. Wotherspoon, J. N. Thompson, J. G. Swansbury, E. Matutes and D. Catovsky
959 **Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10 – a humanized human leucocyte antigen DR antibody**
B. Stockmeyer, M. Schiller, R. Repp, H.-M. Lorenz, J. R. Kalden, M. Gramatzki and T. Valerius
968 **CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells**
R. Buhman, C. Kurzeder, J. Rehklau, D. Westhaus, S. Bursch, W. Hiddemann, T. Haferlach, M. Hallek and C. Schoch

976 **Defective assembly of the B-cell receptor chains accounts for its low expression in B-chronic lymphocytic leukaemia**
B. Payelle-Brogard, C. Magnac, A. Alcover, P. Roux and G. Dighiero

986 **A descriptive study of randomized trials of treatments for childhood acute lymphoblastic leukaemia**
J. A. Burrett and M. J. Clarke

991 **Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance**
M. A. Pulè, C. Gullmann, D. Dennis, C. McMahon, M. Jeffers and O. P. Smith

999 **Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of *MLL* gene status: results of the Japan Infant Leukaemia Study (MLL96)**
K. Isoyama, M. Eguchi, S. Hibi, N. Kinukawa, H. Ohkawa, H. Kawasaki, Y. Kosaka, T. Oda, M. Oda, T. Okamura, S.-i. Nishimura, Y. Hayashi, T. Mori, M. Imaizumi, S. Mizutani, I. Tsukimoto, N. Kamada and E. Ishii

1011 **Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia**
E. Carlotti, F. Pettenella, R. Amaru, S. Slater, T. A. Lister, T. Barbui, G. Basso, G. Cazzaniga, A. Rambaldi and A. Biondi

1019 **The use of anti-T-cell receptor-Vβ antibodies for the estimation of treatment success and phenotypic characterization of clonal T-cell populations in cutaneous T-cell lymphomas**
C. Schwab, J. Willers, E. Niederer, E. Ludwig, T. Kündig, P. Grob, G. Burg and R. Dummer

1027 **Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow**
J. P. van Dijk, G. H. J. N. Knops, A. T. F. van de Locht, A. L. Menke, J. H. Jansen, E. J. B. M. Mensink, R. A. P. Raymakers and T. de Witte

1034 **Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival**
M. V. Mateos, R. García-Sanz, R. López-Pérez, M. J. Moro, E. Ocio, J. Hernández, M. Megido, M. D. Caballero, J. Fernández-Calvo, A. Bárez, J. Almeida, A. Orfão, M. González and J. F. San Miguel

1041 **Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma**
A. B.-T. Fassas, T. Spencer, J. Sawyer, M. Zangari, C.-K. Lee, E. Anaissie, F. Muwalla, C. Morris, B. Barlogie and G. Tricot

1048 **Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase – a report from the Swedish CML Group**
U. Axdorph, L. Stenke, G. Grimfors, J. Carneskog, J. Hansen, O. Linder, P. Ljungman, E. Löfvenberg, C. Malm, B. Simonsson, I. Turesson, L. Vilén, A.-M. Udén and M.Björkholm for the Swedish CML Group

1055 **Hodgkin and Reed–Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor**
D. Aldinucci, D. Poletto, P. Nanni, M. Degan, A. Gloghini, R. Di Francia, S. Russo, A. Carbone, A. Pinto and V. Gattei

1065 **Gene expression analysis of $1,25(OH)_2D_3$-dependent differentiation of HL-60 cells: a cDNA array study**
H. Savli, Y. Aalto, B. Nagy, S. Knuutila and S. Pakkala

1071 **Sex ratios and the risks of haematological malignancies**
R. A. Cartwright, K. A. Gurney and A. V. Moorman

Short reports 1078 **Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome**
B. T. Heelan, V. Tormey, P. Amlot, E. Payne, A. Mehta and A. D. B. Webster

1082 **Acquired trisomy 21 and distinct clonal evolution in acute megakaryoblastic leukaemia in young monozygotic twins**
B. Stark, M. Jeison, C. Preudhomme, P. Fenaux, S. Ash, Y. Korek, J. Stein, R. Zaizov and I. Yaniv

TRANSPLANTATION

1087 **Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide**
J.-H. Lee, K.-H. Lee, J.-H. Lee, S. Kim, M. Seol, C.-J. Park, H.-S. Chi, W. Kang, S. T. Kim, W.-K. Kim and J.-S. Lee

1095 **CD34$^+$-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back**
M. Bornhäuser, U. Platzbecker, C. Theuser, K. Hölig and G. Ehninger

1104 **Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation**
T. Demirer, M. Ayli, M. Dagli, R. Haznedar, Y. Genc, T. Fen, S. Dincer, E. Unal, N. Gunel, E. Seyrek, T. Ustun, N. Ustael, M. Yildiz, D. Sertkaya, G. Ozet and O. Muftuoglu

1112 **Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT)**
T. Ruutu, J. Hermans, D. Niederwieser, A. Gratwohl, M. Kiehl, L. Volin, H. Bertz, P. Ljungman, D. Spence, L. F. Verdonck, H. G. Prentice, A. Bosi, C. E. du Toit, L. Brinch and J. F.Apperley on behalf of the EBMT Chronic Leukaemia Working Party

Short reports 1120 **Identification of early antigen BZLF1/ZEBRA protein of Epstein–Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease**
S. H. Oertel, I. Anagnostopoulos, M. W. Hummel, S. Jonas and H. B. Riess

1124 **The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation**
M. D. Ronghe, A. B. M. Foot, J. M. Cornish, C. G. Steward, D. Carrington, N. Goulden, D. I. Marks, A. Oakhill and D. H. Pamphilon

1128 **Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype**
S. T. Lee, J. H. Jang, J.-W. Cheong, J. S. Kim, H.-Y. Maemg, J. S. Hahn, Y. W. Ko and Y. H. Min

PLATELETS, HAEMOSTASIS AND THROMBOSIS

1132 **Many $\alpha_{IIb}\beta_3$ autoepitopes in chronic immune thrombocytopenic purpura are localized to α_{IIb} between amino acids L1 and Q459**
R. Mcmillan, L. Wang, J. Lopez-Dee, S. Jiu and J. C. Loftus

1137 **Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin**
E. Lindhoff-Last, R. Nakov, F. Misselwitz, H.-K. Breddin and R. Bauersachs

1143 **A Ser^{752}→Pro substitution in the cytoplasmic domain of β3 in a Glanzmann thrombasthenia variant fails to prevent interactions between the $\alpha_{IIb}\beta3$ integrin and the platelet granule pool of fibrinogen**
P. Nurden, C. Poujol, J. Winckler, R. Combrié, J. P. Caen and A. T. Nurden

1152 **Enhancement of human platelet activation by the combination of low concentrations of collagen and rabbit anticardiolipin antibodies**
L. Wang, C.-Y. Su, K.-Y. Chou and C.-T. Wang

Short report 1163 **X-linked thrombocytopenia in a girl**
H. Inoue, H. Kurosawa, S. Nonoyama, K. Imai, H. Kumasaki, T. Matsunaga, Y. Sato, K. Sugita and M. Eguchi

RED CELLS

1166 **Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism**
V. Pullarkat, M. Ngo, S. Iqbal, B. Espina and H. A. Liebman

1170 **Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people**
Y. Deugnier, A.-M. Jouanolle, J. Chaperon, R. Moirand, C. Pithois, J.-F. Meyer, M. Pouchard, B. Lafraise, A. Brigand, C. Caserio-Schoenemann, J. Mosser, P. Adams, J.-Y. Le Gall and V. David

Short report 1179 **Mutation spectrum in Australian pedigrees with hereditary hyperferritinaemia–cataract syndrome reveals novel and *de novo* mutations**
J. L. Mcleod, J. Craig, S. Gumley, S. Roberts and M. A. Kirkland

TRANSFUSION

Short reports 1183 **Treatment of life-threatening post-haemorrhagic anaemia with cell-free haemoglobin solution in an adolescent Jehovah's Witness**
N. Anton, J. K. Hitzler and B. P. Kavanagh

1187 **Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin**
F. Hayakawa, K. Imada, M. Towatari and H. Saito

CORRESPONDENCE

1190 **Is there a relationship between *in vitro* drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia?**
V. de Haas, G. J. L. Kaspers, L. Oosten, D. Bresters, R. Pieters, V. H. J. van der Velden, E. R. van Wering, H. van den Berg and C. E. van der Schoot

1192 **Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia**
M. Batlle, J.-M. Ribera, A. Oriol, E. Plensa, F. Millá and E. Feliu

1193 **Long-term remissions with weekly chlorambucil therapy in patients with intermediate-risk chronic lymphocytic leukaemia**
A. Manoharan

1194 **Relative erythrocytosis**
F. Haurani

1194 **Reply to Haurani**
H. Blacklock and G. Royle

1194 **Diagnosis and management of multiple myeloma**
S. A. Ely

1195 **Reply to Ely**
A. G. Smith and D. Samson

1195 **Constitutional pericentric inversion of chromosome 9 and haemopoietic stem cell transplantation: delayed engraftment**
S. Imashuku, M. Naya, B. An, Y. Nakabayashi, K. Kuriyama, I. Udeda, A. Morimoto, S. Hibi and S. Todo

1197 **Change in serum procalcitonin (ΔPCT) predicts the clinical outcome of children admitted with febrile neutropenia**
C. Barnes, V. Ignjatovic, F. Newall, J. Carlin, F. Ng, S. Hamilton, D. Ashley, K. Waters and P. Monagle

1198 ***Helicobacter pylori* infection and idiopathic thrombocytopenic purpura**
G. Emilia, M. Luppi, M. Morselli, L. Potenza, N. D'Apollo and G. Torelli

1199 **KILT syndrome?**
J. Van Veen, K. K. Hampton and M. Makris

1201 **ERRATA**

1202 **AUTHOR AND KEYWORD INDEXES FOR VOLUME 118**